

PRODUCT MONOGRAPH

Pr **AROMASIN***

exemestane

Tablets, 25 mg

Professed Standard

Aromatase Inactivator; Anti-Tumour Agent

Pfizer Canada Inc.
17,300 Trans-Canada Highway
Kirkland, Quebec
H9J 2M5

Date of Revision:
March 6, 2018

Submission Control No: 204398

* TM Pfizer Enterprises SARL
Pfizer Canada Inc., Licensee

©Pfizer Canada Inc 2018

Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION.....	3
SUMMARY PRODUCT INFORMATION	3
INDICATIONS AND CLINICAL USE.....	3
CONTRAINDICATIONS	3
WARNINGS AND PRECAUTIONS.....	4
ADVERSE REACTIONS.....	8
DRUG INTERACTIONS	15
DOSAGE AND ADMINISTRATION.....	15
OVERDOSAGE	16
ACTION AND CLINICAL PHARMACOLOGY	16
STORAGE AND STABILITY.....	19
SPECIAL HANDLING INSTRUCTIONS	19
DOSAGE FORMS, COMPOSITION AND PACKAGING	20
PART II: SCIENTIFIC INFORMATION	21
PHARMACEUTICAL INFORMATION.....	21
CLINICAL TRIALS.....	22
DETAILED PHARMACOLOGY	34
TOXICOLOGY	37
REFERENCES	41
PART III: CONSUMER INFORMATION.....	45

AROMASIN

exemestane

PART I: HEALTH PROFESSIONAL INFORMATION

SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Oral	tablet 25 mg	Not applicable. <i>For a complete listing see Dosage Forms, Composition and Packaging section.</i>

INDICATIONS AND CLINICAL USE

AROMASIN (exemestane) is indicated for the sequential adjuvant treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy.

Approval is based on improved disease-free survival for sequential AROMASIN in comparison to continuous tamoxifen. However, overall survival was not significantly different between the two treatments (see PART II, CLINICAL TRIALS).

AROMASIN (exemestane) is also indicated for hormonal treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status whose disease has progressed following antiestrogen therapy.

CONTRAINDICATIONS

AROMASIN (exemestane) Tablets are contraindicated in patients with a known hypersensitivity to the drug or to any of the excipients.

WARNINGS AND PRECAUTIONS

Serious Warnings and Precautions

Aromasin should be administered under the supervision of a qualified physician experienced in the use of anti-cancer agents.

- Not recommended for use in pre-menopausal women (see General section below)
- Osteoporosis (see Musculoskeletal section below).

General:

AROMASIN should not be administered to women with premenopausal endocrine status as safety and efficacy have not been established in these patients. AROMASIN should not be coadministered with estrogen-containing agents as these could interfere with its pharmacologic action.

Drug Interactions

In patients receiving tamoxifen and warfarin concurrently, re-titration of the warfarin dose may be required following the switch from tamoxifen to exemestane. Possible interaction between tamoxifen and warfarin that required dose adjustments have been described. As a result, patients on warfarin treatment were excluded from the IES trial because the risk of experiencing a coagulation problem in switching from previous tamoxifen to exemestane could not be excluded. Although a potential interaction between warfarin and exemestane has not been studied clinically, *in vitro* studies have demonstrated that exemestane does not inhibit the activity of CYP2C9 (enzyme responsible for the metabolism of s-warfarin) and exemestane is not anticipated to alter the pharmacokinetics of warfarin. Therefore, the dosage of warfarin should be controlled by periodic determinations of prothrombin times (PT) ratio/International Normalized Ratio (INR) or other suitable coagulation tests at the time of switch from tamoxifen to exemestane as per recommendations in the warfarin Product Monograph

Effects on Coagulation

To date, there is no indication that exemestane affects antithrombin III. Some steroidal compounds are known to affect antithrombin III, increasing the risk of thromboembolic events. Preclinical data evaluating exemestane's potential to affect antithrombin III is not available; however, studies in humans are ongoing. In a study in postmenopausal women with early breast cancer at low risk treated with exemestane (n=73) or placebo (n=73) (Study 027), there was no change in the coagulation parameters activated partial thromboplastin time [APTT], prothrombin time [PT] and fibrinogen.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

In a carcinogenicity study conducted in rats, exemestane was administered by gavage at doses of 30, 100 and 315 mg/kg/day for 92 weeks in males and 104 weeks in females. No evidence of carcinogenic activity was observed in female rats. The male rat study was inconclusive since it was terminated prematurely at Week 92.

In a 2-year carcinogenicity study in mice, exemestane, dosed at 50, 150 and 450 mg/kg/day, induced an increased incidence of hepatocellular adenomas and carcinomas at the high dose in both sexes. An increased incidence of renal tubular adenomas was also observed in male mice at

the high dose. Plasma levels in male and female mice at the high dose were approximately 34 and 75-fold higher than the AUC in postmenopausal patients at the therapeutic dose. Since the doses tested in mice did not achieve an MTD, neoplastic findings in organs other than liver and kidneys remain unknown. (see **Toxicology: Carcinogenicity**).

Cardiovascular disease

The use of aromatase inhibitors, including AROMASIN, may increase the risk of ischemic cardiovascular diseases. During the Intergroup Exemestane Study (IES), more patients receiving exemestane were reported to have ischemic cardiac events (myocardial infarction, angina, and myocardial ischemia) compared to patients receiving tamoxifen (treatment-emergent cases: 2.0% versus 1.3%; all-cases [either on treatment or during follow up]: 5.8% versus 3.8%). In addition, a larger number of events were reported for exemestane in comparison to tamoxifen for some individual treatment-emergent cardiovascular events including hypertension (9.9% versus 8.4%), myocardial infarction (0.6% versus 0.2%) and cardiac failure (1.1% versus 0.7%). Women with significant cardiac disorders were excluded from the clinical studies of exemestane in early breast cancer.

Endocrine and Metabolism

The use of aromatase inhibitors, including AROMASIN, may increase the occurrence of hypercholesterolemia. During the IES study, more patients receiving exemestane were reported to have treatment-emergent hypercholesterolemia compared to patients receiving tamoxifen (3.7% vs. 2.1%, respectively).

In a study in postmenopausal women with early breast cancer at low risk treated with exemestane (n=73) or placebo (n=73) (Study 027) plasma HDL cholesterol was decreased 6-9% in exemestane-treated patients; total cholesterol, LDL-cholesterol, triglycerides, apolipoprotein-A1, apolipoprotein-B, and lipoprotein-a were unchanged. An 18% increase in homocysteine levels was observed in exemestane-treated patients compared with a 12% increase seen with placebo. Exemestane induced a significant increase in both bone formation and bone resorption markers [bone-specific alkaline phosphatase (BAP), serum procollagen type I N propeptide (PINP) and serum osteocalcin; serum and urinary C-terminal cross-linked telopeptide of type I collagen (CTX-I), and urinary N-terminal cross-linked telopeptide of type I collagen (NTX-I)].

Gastrointestinal

The use of AROMASIN may increase the risk of gastric ulcer. In the early breast cancer IES trial, gastric ulcer was observed at a slightly higher frequency in the exemestane arm compared to tamoxifen (0.7% versus <0.1%). The majority of patients on exemestane with gastric ulcer received concomitant treatment with non-steroidal anti-inflammatory agents and /or had a prior history.

Hematologic

In patients with early breast cancer (IES Study) the incidence of hematological abnormalities of Common Toxicity Criteria (CTC) grade ≥ 1 was lower in the exemestane treatment group, compared with tamoxifen. Incidence of CTC grade 3 or 4 abnormalities was low (approximately 0.1%) in both treatment groups. Approximately 20% of patients receiving AROMASIN in clinical studies in advanced breast cancer, particularly those with pre-existing lymphocytopenia,

experienced a moderate transient decrease in lymphocytes. However, mean lymphocyte values in these patients did not change significantly over time. Patients did not have a significant increase in viral infections, and no opportunistic infections were observed.

Hepatic/Biliary/Pancreatic

In patients with early breast cancer, elevations in bilirubin and alkaline phosphatase were more common in those receiving exemestane than either tamoxifen or placebo. Treatment emergent bilirubin elevations occurred in 5.9% of exemestane-treated patients compared to 0.9% of tamoxifen-treated patients on the IES, and in 6.9% of exemestane-treated patients versus 0% of placebo-treated patients on the 027 study; CTC grade 3-4 increases in bilirubin occurred in 0.9% of exemestane-treated patients compared to 0.1% of tamoxifen-treated patients on the IES. Alkaline phosphatase elevations occurred in 15.9% of exemestane-treated patients compared to 3.1% of tamoxifen-treated patients on the IES, and in 13.7% of exemestane-treated patients compared to 6.9% of placebo-treated patients on Study 027.

In patients treated for advanced breast cancer, elevation of the serum levels of AST, ALT, alkaline phosphatase and gamma glutamyl transferase >5 times the upper value of the normal range have been reported rarely. These changes were mostly attributable to the underlying presence of liver and/or bone metastases. However, in the Phase III study in advanced breast cancer patients, elevation of the gamma glutamyl transferase without documented evidence of liver metastasis was reported in 2.7% of patients treated with AROMASIN and in 1.8% of patients treated with megestrol acetate. Additionally, in post-market surveillance elevations of the serum levels of AST, ALT, alkaline phosphatase and gamma glutamyl transferase >5 times the upper value of the normal range were not necessarily due to liver or bone metastases and normalization of liver enzyme values post discontinuation of drug has been observed.

Rare cases of hepatitis including cholestatic hepatitis have been observed in other clinical trials with additional reports identified through post-marketing surveillance.

Musculoskeletal

The use of estrogen lowering agents, including AROMASIN, may cause a reduction in bone mineral density (BMD) with a possible consequent increased risk of fracture. Women should have their osteoporosis risk assessed and managed according to local clinical practice and guidelines. Women with clinical evidence of severe osteoporosis or a history of osteoporotic fracture were excluded from the clinical studies of exemestane in early breast cancer.

Reductions in BMD over time were seen with exemestane use in these clinical trials; Table 1 describes changes in BMD from baseline to 24 months in patients receiving exemestane compared to patients receiving tamoxifen (IES) or placebo (027).

Table 1: Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control

BMD	IES		027	
	Exemestane	Tamoxifen	Exemestane N=59	Placebo N=65
Lumbar spine (%)	-3.68 (N=82)	-0.19 (N=94)	-3.51	-2.39
Femoral neck (%)	-3.96 (N=77)	-0.69 (N=87)	-4.57	-2.59

The use of aromatase inhibitors, including AROMASIN, may cause arthralgias and/or myalgias, which may impact on treatment compliance and quality of life. In the IES study, 17.6% of patients in exemestane arm reported arthralgia as an adverse event versus 10.8% of patients in tamoxifen arm. Arthralgia-related disorders such as arthralgia, back pain, and pain in limb led to study drug discontinuation more often in AROMASIN-treated patients than tamoxifen-treated patients (1.3% versus 0.3% of total patients treated, respectively).

Renal

In patients with early breast cancer, elevations in creatinine were more common in those receiving exemestane than either tamoxifen or placebo. Creatinine elevations occurred in 6.4% of exemestane-treated patients versus 5.0% of tamoxifen-treated patients on the IES and in 5.5% of exemestane-treated patients versus 0% of placebo-treated patients on Study 027.

Skin

Severe cutaneous reactions erythema multiforme and acute generalized exanthematus pustulosis (AGEP) have been reported in association with AROMASIN. The latency of AGEP was 2 weeks after starting exemestane treatment, which is consistent with the temporal pattern of drug-related AGEP. Patients that experience severe cutaneous reactions should permanently discontinue AROMASIN.

Special population

Pregnant Women:

AROMASIN (exemestane) should not be used in women who are or may become pregnant because it may cause harm to the fetus. Exemestane caused placental enlargement, dystocia, and prolonged gestation when given to pregnant rats at doses greater than 4 mg/kg/day (24 mg/m²/day), approximately 1.5 times the recommended human daily dose (16.0 mg/m²/day) on a mg/m² basis. There are no adequate and well-controlled studies in pregnant women using exemestane. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus or the potential risk for loss of the pregnancy.

Increased resorption, reduced number of live fetuses, decreased fetal weight, and retarded ossification were also observed at these doses. The administration of exemestane to pregnant rats at doses of 50 mg/kg/day during the organogenesis period caused an increase in fetal resorption, but there was no evidence of teratogenicity up to the dose of 810 mg/kg/day (4860 mg/m²/day).

Daily doses of exemestane 270 mg/kg/day (4320 mg/m²/day), which is greater than 200 times the recommended human daily dose, given to rabbits during organogenesis caused abortions, an increase in resorptions, and a reduction in fetal body weight; there was no increase in the incidence of malformations (see **TOXICOLOGY: Reproduction and Teratology**).

Hepatic Impairment:

Following a single 25-mg oral dose, the AUC of exemestane in patients with hepatic dysfunction (moderate hepatic impairment, Child Pugh B; severe hepatic impairment, Child Pugh C) was

approximately 3 times higher than that observed in healthy volunteers. However, no dosage adjustment is required for patients with liver impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended 25 mg daily dose (see **ACTION AND CLINICAL PHARMACOLOGY**).

Renal Impairment:

The AUC of exemestane after a single 25-mg dose was approximately 3 times higher in subjects with severe renal insufficiency (creatinine clearance <30 mL/min/1.73 m²) compared with the AUC in healthy volunteers. However, no dosage adjustment is required for patients with renal impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended dose (see **ACTION AND CLINICAL PHARMACOLOGY**).

Nursing Women:

Although it is not known whether exemestane is excreted in human milk, the drug was shown to be excreted in the milk of lactating rats. Because there is a potential for serious adverse reactions in nursing infants, nursing should be discontinued when receiving therapy with AROMASIN.

Pediatrics:

The safety and effectiveness of AROMASIN in pediatric patients have not been established.

Geriatrics:

Healthy postmenopausal women aged 43 to 68 years were studied in the pharmacokinetic trials. Age-related alterations in exemestane pharmacokinetics were not seen over this age range (see **ACTION AND CLINICAL PHARMACOLOGY**).

Monitoring and Laboratory Tests:

Women should have their cholesterol levels and osteoporosis risks assessed and managed according to current clinical practice and guidelines.

ADVERSE REACTIONS

Adjuvant Treatment of Early Breast Cancer

Adverse Drug Reaction Overview:

AROMASIN (exemestane) Tablets tolerability in postmenopausal women with early breast cancer was evaluated in two well-controlled trials: the Intergroup Exemestane Study 031 (IES) (see **CLINICAL STUDIES**) and the 027 study (a randomized, placebo-controlled, double-blind, parallel group, phase II study specifically designed to assess the effects of exemestane on bone metabolism, hormones, lipids and coagulation factors over 2 years of treatment).

Certain adverse events, expected based on the known pharmacological properties and side effect profiles of test drugs, were actively sought through a positive checklist. Signs and symptoms were graded for severity using CTC in both studies. Within the IES study, the presence of some

illnesses/conditions was monitored through a positive checklist without assessment of severity. These included myocardial infarction, other cardiovascular disorders, gynecological disorders, osteoporosis, osteoporotic fractures, other primary cancer, and hospitalizations.

The median duration of adjuvant treatment was 30.0 months and 29.9 months for patients receiving AROMASIN or tamoxifen, respectively, within the IES study, and 23.9 months for patients receiving AROMASIN or placebo within the 027 study. Median duration of observation after randomization at the time of primary analysis, for AROMASIN was 40.4 months and for tamoxifen 39.1 months; and at the time of the updated analysis for AROMASIN was 53.6 months and for tamoxifen 51.6 months. Median duration of observation was 30 months for both groups in the 027 study.

AROMASIN was generally well tolerated, and adverse events were usually mild to moderate. Within the IES study discontinuations due to adverse events occurred in 7.4% and 6.2% of patients receiving AROMASIN and tamoxifen, respectively, and in 12.3% and 4.1% of patients receiving exemestane or placebo within Study 027. Within the IES study, the most commonly reported adverse reactions were hot flushes (AROMASIN 22%; tamoxifen 20%), arthralgias (AROMASIN 18%; tamoxifen 11%), and fatigue (AROMASIN 16%; tamoxifen 15%). On-treatment deaths due to any cause were reported for 1.5% of the exemestane-treated patients, and 1.5% of the tamoxifen-treated patients within the IES study. There were 6 on-treatment deaths due to stroke and 3 due to cardiac failure in the AROMASIN-treated patients compared with 2 deaths due to stroke and 1 due to cardiac failure in the tamoxifen-treated patients. There were no deaths in Study 027.

Clinical Trial Adverse Drug Reactions:

Treatment-emergent adverse events and illnesses including all causalities and occurring with an incidence of $\geq 5\%$ in either treatment group of the IES study during or within one month of the end of treatment are shown in Table 2.

Table 2: Incidence (%) of Adverse Events of all Grades¹ and Illnesses Occurring in ≥5% of Patients in Any Treatment Group in Study IES in Postmenopausal Women with Early Breast Cancer

Body system and Adverse Event by MedDRA dictionary	% of patients	
	AROMASIN 25 mg daily (N=2249)	Tamoxifen 20 mg daily ² (N=2279)
Gastrointestinal disorders Nausea ³	8.9	9.1
General disorders and administration site conditions Fatigue ³	16.3	15.1
Investigations Weight increased	5.7	6.1
Musculoskeletal and connective tissue disorders Arthralgia Pain in limb Back pain Osteoarthritis Osteoporosis	17.6 6.4 9.3 6.1 5.2	10.8 4.7 7.7 4.7 2.9
Nervous system disorders Headache ³ Dizziness ³	13.6 10.0	11.2 8.8
Psychiatric disorders Insomnia ³ Depression	12.9 6.2	9.0 5.6
Reproductive system and breast disorders Vaginal hemorrhage	4.0	5.3
Skin and subcutaneous tissue disorders Increased sweating ³	12.0	10.6
Vascular Hot flushes ³ Hypertension ³	21.8 9.9	20.1 8.4

¹ Graded according to Common Toxicity Criteria;

² 75 patients received tamoxifen 30 mg daily;

³ Event actively sought

In the IES study, more patients receiving exemestane were reported to have ischemic cardiac events (myocardial infarction, angina, and myocardial ischemia) compared to patients receiving tamoxifen (treatment-emergent cases: 2.0% versus 1.3%; all-cases [either on treatment or during follow up]: 5.8% versus 3.8%). No significant difference was noted for any individual treatment-emergent cardiovascular event including hypertension (9.9% versus 8.4%), myocardial infarction (0.6% versus 0.2%) and cardiac failure (1.1% versus 0.7%). The proportion of patients reporting hypercholesterolemia was 3.7% in the AROMASIN-treated group versus 2.1% in the tamoxifen-treated group.

In the IES study, as compared to tamoxifen, AROMASIN was associated with a higher incidence of events in the musculoskeletal disorders and in the nervous system disorders, including the following events occurring with frequency lower than 5%: paraesthesia (2.8% vs. 1.0%), carpal tunnel syndrome (2.8% vs. 0.2%) and neuropathy (0.5% vs. <0.1%).

AROMASIN was associated with a significantly higher incidence of gastric ulcer events in comparison to tamoxifen (0.7% vs. <0.1%). In addition, diarrhea was also more frequent in the AROMASIN group (4.2% vs. 2.2%). The majority of patients on AROMASIN with gastric ulcer received concomitant treatment with non-steroidal anti-inflammatory agents and/or had a prior history.

Clinical fractures were reported in 101 patients receiving exemestane (4.5%) and 75 patients receiving tamoxifen (3.3%).

Tamoxifen was associated with a greater incidence of muscle cramps (3.2% vs. 1.4%), uterine polyps (1.8% vs. 0.4%), venous thromboembolic disease (1.8% vs. 0.7%), endometrial hyperplasia (0.9% vs. <0.1%) and uterine polypectomy (0.8% vs. 0.2%).

A lower incidence of other second (non-breast) primary cancers was observed in the AROMASIN-treated patients versus tamoxifen-treated patients (3.6% vs. 5.3%) in the IES study.

Based on reports of adverse events in 73 postmenopausal women in each treatment group in the 027 study, Table 3 shows treatment-emergent adverse events including all causalities and occurring with an incidence of $\geq 5\%$ in either treatment group.

Table 3: Incidence (%) of Adverse Events of all Grades¹ Occurring in ≥5% of Patients in either Treatment Group in Study 027

Body system and Adverse Event by MedDRA dictionary	% of patients	
	AROMASIN 25 mg daily (N=73)	Placebo (N=73)
Gastrointestinal disorders		
Nausea	12.3	16.4
Abdominal pain	11.0	13.7
Diarrhea	9.6	1.4
General disorders and administration site conditions		
Fatigue	11.0	19.2
Musculoskeletal and connective tissue disorders		
Arthralgia	28.8	28.8
Pain in limb	8.2	6.9
Myalgia	5.5	4.1
Tendonitis	5.5	5.5
Nervous system disorders		
Dizziness	9.6	9.6
Headache	6.9	4.1
Psychiatric disorders		
Insomnia	13.7	15.1
Depression	9.6	6.9
Anxiety	4.1	5.5
Infections and infestations		
Urinary tract infection	8.2	8.2
Skin and subcutaneous tissue disorders		
Increased sweating	17.8	20.6
Alopecia	15.1	4.1
Dermatitis	6.9	1.4
Vascular disorders		
Hot flushes	32.9	24.7
Hypertension	15.1	6.9

¹ Graded according to Common Toxicity Criteria

Events were mostly grade 1 or 2 in severity for both AROMASIN and placebo treated patients.

Treatment of Advanced Breast Cancer after Failure on Tamoxifen:

Adverse Drug Reaction Overview:

A total of 1058 patients who had failed prior tamoxifen therapy were treated with AROMASIN (exemestane) Tablets 25 mg once daily in the clinical trials program. AROMASIN was generally well tolerated and adverse events were usually mild to moderate. Only one death was potentially related to treatment with AROMASIN; an 80-year-old woman with known coronary artery disease had a myocardial infarction with multiple organ failure after 9 weeks on study treatment. In the clinical trials program, only 2.8% of the patients discontinued treatment with AROMASIN because of adverse events, mainly within the first 10 weeks of treatment; late discontinuations due to adverse events were uncommon (0.3%).

Clinical Trial Adverse Drug Reactions:

In the Phase III study, 358 patients were treated with AROMASIN and 400 patients were treated with megestrol acetate. Fewer patients receiving exemestane discontinued treatment because of adverse events than those treated with megestrol acetate (1.7% versus 5%). Adverse events in the Phase III study that were considered drug related or of indeterminate cause included hot flashes (12.6%), nausea (9.2%), fatigue (7.5%), increased sweating (4.5%), and increased appetite (2.8%). The proportion of patients experiencing an excessive weight gain (>10% of their baseline weight) was significantly higher with megestrol acetate than with exemestane (17.1% versus 7.6%, p=0.001). The following table (Table 4) shows the adverse events of all National Cancer Institute (NCI) Common Toxicity grades regardless of causality reported in 5% or greater of patients in the Phase III study treated either with AROMASIN or megestrol acetate.

Table 4: Incidence (%) of Adverse Events of all NCI* Common Toxicity Grades and Causes Occurring in >5% of Patients in the Phase III Study

Event	AROMASIN 25 mg once daily (N=358)	Megestrol Acetate 40 mg QID (N=400)
Any Adverse Event	79.3	80
Skin and subcutaneous tissue disorders		
Increased sweating	6.1	9.0
General Disorders and Administration Site Conditions		
Fatigue	21.8	29.3
Pain	13.1	12.5
Influenza-like symptoms	5.9	5.3
Vascular disorders		
Hypertension	4.7	5.8
Hot flushes	13.4	5.5
Psychiatric Disorders		
Depression	12.8	8.8
Insomnia	10.9	9.0
Anxiety	10.1	10.8
Dizziness	8.1	5.8
Headache	8.1	6.5
Gastrointestinal disorders		
Nausea	18.4	11.5
Vomiting	7.3	3.8
Abdominal pain	6.1	10.5
Anorexia	6.1	4.8
Constipation	4.7	8.0
Diarrhea	3.6	5.0
Metabolism and nutrition disorders		
Increased appetite	2.8	5.8
Respiratory, thoracic and mediastinal disorders		
Dyspnea	9.8	15.0
Coughing	5.9	7.0

* NCI = National Cancer Institute

In the overall clinical trials program for advanced cancer (N = 1058), additional adverse events reported in 5% or greater of patients treated with AROMASIN 25 mg once daily included pain at tumor site (8%), peripheral edema (7.6%), asthenia (5.8%) and fever (5%). Less frequent but common adverse events (1% to 5%) reported in these patients were liver enzyme abnormalities (AST, ALT, alkaline phosphatase), elevated bilirubin, arthralgia, peripheral edema, back pain, dyspepsia, paresthesia, bronchitis, rash, chest pain, edema, hypertension, upper respiratory tract infection, pruritus, urinary tract infection, pathological fracture, alopecia, leg edema, sinusitis, skeletal pain, infection, pharyngitis, rhinitis, hypoesthesia, confusion, and lymphedema.

Post-Market Adverse Drug Reactions

Post-market adverse events/illnesses include case observed in other clinical trials (not described above) as well as reports from post-marketing surveillance. Because these events are not uniformly reported, it is not always possible to reliably estimate their frequency or clearly establish a causal relationship to AROMASIN exposure. The following events are listed according to MedDRA system organ class.

Vascular disorders: Cerebrovascular accident, pulmonary embolus and deep vein thrombosis were among the most frequently reported adverse events/illnesses in the post-market setting.

Cardiac disorders: Cardiac failure and myocardial infarction have been reported in association with AROMASIN.

Nervous System disorders: Carpal tunnel and paraesthesia has been reported frequently in the post-market setting.

Hepatobiliary disorders: Rare cases of hepatitis including cholestatic hepatitis have been observed in other clinical trials with additional reports identified through post-marketing surveillance.

Investigations: ALT, AST, blood bilirubin and blood alkaline phosphatase increases that have been reported as common events above have also been reported as very common events in other clinical trials. Additionally, in post-market surveillance elevation of the serum levels of AST, ALT, alkaline phosphatase and gamma glutamyl transferase >5 times the upper value of the normal range have been observed. Increase in liver enzymes was not necessarily due to liver or bone metastases and normalization of liver enzyme values post discontinuation of drug has been observed.

Skin and subcutaneous tissue disorders: Severe cutaneous reactions erythema multiforme and acute generalized exanthematus pustulosis have been reported in association with AROMASIN. Urticaria and pruritus have also been reported in association with AROMASIN.

Immune System disorders: Hypersensitivity, including anaphylactic reactions, has occurred between 8 hours to 26 days of starting exemestane therapy.

DRUG INTERACTIONS

Drug-Drug Interactions:

In vitro evidence showed that AROMASIN (exemestane) is metabolized by cytochrome P450 (CYP) 3A4 and aldoketoreductases, and does not inhibit any of the major CYP isoenzymes, including CYP 1A2, 2C9, 2D6, 2E1, and 3A. In a clinical pharmacokinetic study, the specific inhibition of CYP3A4 by ketoconazole administration showed no significant influence on the pharmacokinetics of exemestane. Although pharmacokinetic effects were observed in a pharmacokinetic interaction study with rifampin, a potent CYP3A4 inducer, the suppression of plasma estrogen concentrations (estrone sulfate) produced by exemestane was not affected and a dosage adjustment is not required.

In patients receiving tamoxifen and warfarin concurrently, re-titration of the warfarin dose may be required following the switch from tamoxifen to exemestane. Possible interaction between tamoxifen and warfarin that required dose adjustments have been described. As a result, patients on warfarin treatment were excluded from the IES trial because the risk of experiencing a coagulation problem in switching from previous tamoxifen to exemestane could not be excluded. Although a potential interaction between warfarin and exemestane has not been studied clinically, *in vitro* studies have demonstrated that exemestane does not inhibit the activity of CYP2C9 (enzyme responsible for the metabolism of s-warfarin) and exemestane is not anticipated to alter the pharmacokinetics of warfarin. Therefore, the dosage of warfarin should be controlled by periodic determinations of prothrombin times (PT) ratio/International Normalized Ratio (INR) or other suitable coagulation tests at the time of switch from tamoxifen to exemestane as per recommendations in the warfarin Product Monograph.

Drug-Laboratory Interactions:

No clinically relevant changes in the results of clinical laboratory tests have been observed.

DOSAGE AND ADMINISTRATION

Recommended Dose and Dosage Adjustment:

The recommended dose of AROMASIN (exemestane) Tablets in early and advanced breast cancer is 25 mg once daily after a meal.

In postmenopausal women with early breast cancer, treatment with AROMASIN should continue until completion of five years of adjuvant endocrine therapy, or until local or distant recurrence or new contralateral breast cancer.

In patients with advanced breast cancer, treatment with AROMASIN should continue until tumor progression is evident.

No dose adjustments are required for patients with hepatic or renal insufficiency.

OVERDOSAGE

For management of a suspected drug overdose, contact your regional Poison Control Centre.

Clinical trials have been conducted with AROMASIN (exemestane) Tablets given up to 800 mg as a single dose to healthy female volunteers and up to 600 mg daily for 12 weeks to postmenopausal women with advanced breast cancer. These dosages were well tolerated. There is no specific antidote to overdose and treatment must be symptomatic. General supportive care, including frequent monitoring of vital signs and close observation of the patient, is indicated.

A male child (age unknown) accidentally ingested a 25-mg tablet of exemestane. The initial physical examination was normal, but blood tests performed 1 hour after ingestion indicated leucocytosis (WBC:25000/mm³ with 90% neutrophils). Blood tests were repeated 4 days after the incident and were normal. No treatment was given.

In rats and dogs, mortality was observed after single oral doses of 5000 mg/kg (about 2000 times the recommended human dose on a mg/m² basis) and of 3000 mg/kg (about 4000 times the recommended human dose on a mg/m² basis), respectively.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action:

Breast cancer cell growth is often estrogen-dependent and anti-tumour activity is expected following effective and continuous estrogen suppression in patients with hormone-sensitive breast cancer. Aromatase is the key enzyme that converts androgens to estrogens both in pre- and postmenopausal women. While the main source of estrogen (primarily estradiol) is the ovary in premenopausal women, the principal source of circulating estrogens in postmenopausal women is from conversion of adrenal and ovarian androgens (mainly androstenedione) to estrogens (primarily estrone) by the aromatase enzyme in peripheral tissues. This occurs mainly in the adipose tissue, but also in the liver, muscle, hair follicles, and breast tissue. Estrogen deprivation through aromatase inhibition is an effective and selective treatment for postmenopausal patients with hormone-dependent breast cancer.

AROMASIN (exemestane) is a potent aromatase inactivator, causing estrogen suppression and inhibition of peripheral aromatisation. It is a steroidal irreversible Type I aromatase inhibitor, structurally related to the natural substrate androstenedione. Exemestane is a specific competitive inactivator of human placental aromatase, which has been shown to be more potent than the irreversible aromatase inhibitor formestane or the reversible inhibitor aminoglutethimide *in vitro*.

In vivo studies of aromatase inactivation indicate that exemestane, by the oral route, is several times more potent than formestane. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its

inactivation, an effect also known as “suicide inhibition”. *De novo* aromatase enzyme synthesis is required for recovery of enzyme activity. Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

Pharmacokinetics:

Absorption:

Following oral administration of radiolabeled exemestane, at least 42% of radioactivity was absorbed from the gastrointestinal tract. Maximum exemestane plasma concentration (C_{max}) was observed within 2 hours of receiving exemestane. Exemestane plasma levels increased by approximately 40% after a high-fat breakfast; however, no further effect on estrogen suppression was observed since maximum activity was already achieved under fasting conditions. Exemestane appears to be more rapidly absorbed in women with breast cancer than in healthy women. After repeated doses, mean T_{max} was 1.2 hours in the women with breast cancer and 2.9 hours in the healthy women. Mean AUC values following repeated doses were approximately 2-fold higher in women with breast cancer (75.4 ng.h/mL) compared with healthy women (41.4 ng.h/mL). However, there was considerable overlap between the range of pharmacokinetic parameters observed in these two populations.

Distribution:

Exemestane is distributed extensively into tissues. Exemestane is 90% bound to plasma proteins and the fraction bound is independent of the total concentration. Albumin and α_1 -acid glycoprotein contribute equally to the binding. The distribution of exemestane and its metabolites into blood cells is negligible.

Metabolism and Excretion:

After reaching maximum plasma concentration, exemestane levels declined polyexponentially with a mean terminal half-life of about 24 hours. Following administration of a single oral dose of radiolabeled exemestane, the elimination of drug-related products was essentially complete within 1 week. Approximately equal proportions of the dose were eliminated in urine and feces. The amount of drug excreted unchanged in urine was less than 1% of the dose, indicating that renal excretion is a limited elimination pathway. Exemestane was extensively metabolized, with levels of the unchanged drug in plasma accounting for less than 10% of the total radioactivity. The initial steps in the metabolism of exemestane are oxidation of the methylene group in position 6 and reduction of the 17-keto group with subsequent formation of many secondary metabolites. Each metabolite accounts only for a limited amount of drug-related material. The metabolites are inactive or demonstrate minimal ability to inhibit aromatase compared with the parent drug. Studies using human liver preparations indicate that cytochrome P-450 3A4 (CYP 3A4) is the principal isoenzyme involved in the oxidation of exemestane. Additional studies in humans demonstrated that exemestane does not affect the activity of CYP3A4 to any great extent. No significant inhibition of any of the CYP isoenzymes (including CYP3A4) involved in xenobiotic metabolism was observed in human liver preparations. This would suggest that

possible drug-drug interactions involving inhibition of CYP by co-administration with exemestane are unlikely.

Special Populations and Conditions:

Geriatrics:

Although women ranging in age up to 99 years were enrolled in the clinical studies (see **WARNINGS AND PRECAUTIONS**), healthy postmenopausal women aged 43 to 68 years were enrolled in the pharmacokinetic trials. Age-related alterations in exemestane pharmacokinetics were not seen over this age range.

Gender:

The pharmacokinetics of exemestane following administration of a single, 25 mg tablet to fasted healthy males (mean age 32 years; range 19 to 51 years) or to fasted healthy postmenopausal women (mean age 55 years; range 45 to 68 years) have been compared. Mean C_{max} and AUC values in healthy males (12.3 ± 5.8 ng/mL and 28.4 ± 17.3 ng.h/mL, respectively) were similar to those determined in healthy postmenopausal women (11.1 ± 4.4 ng/mL and 29.7 ± 7.8 ng.h/mL, respectively). Thus, the pharmacokinetics of exemestane does not appear to be influenced by gender.

Race:

The influence of race on exemestane pharmacokinetics has not been formally evaluated.

Hepatic Insufficiency:

The pharmacokinetics of exemestane have been investigated in subjects with moderate and severe hepatic insufficiency. Following a single 25-mg oral dose, the AUC of exemestane was approximately 3 times higher than that observed in healthy volunteers. However no dosage adjustment is required for patients with liver impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended 25-mg daily dose (see **WARNINGS AND PRECAUTIONS**).

Renal Insufficiency:

The AUC of exemestane after a single 25-mg dose was approximately 3 times higher in subjects with severe renal insufficiency (creatinine clearance <30 mL/min/1.73 m²) compared with the AUC in healthy volunteers. However, no dosage adjustment is required for patients with renal impairment since exemestane was well tolerated in patients with breast cancer at doses 8 to 24 times higher than the recommended dose (see **WARNINGS AND PRECAUTIONS**).

Pediatrics:

The pharmacokinetics of exemestane have not been studied in pediatric patients.

STORAGE AND STABILITY

Store between 15° to 30° C.

SPECIAL HANDLING INSTRUCTIONS

Not applicable.

DOSAGE FORMS, COMPOSITION AND PACKAGING

AROMASIN (exemestane) Tablets are round, biconvex, and off-white to slightly gray. Each tablet contains 25 mg of exemestane. The tablets are printed on one side with the number “7663” in black. AROMASIN is supplied as follows:

HDPE bottles of 30 tablets with a child-resistant screw cap: 25 mg.

Aluminium-PVDC/PVC-PVDC opaque white blisters of 30 tablets: 25 mg.

Aluminium-PVDC/PVC-PVDC opaque white blisters of 15 tablets: 25 mg.

Composition:


AROMASIN Tablets for oral administration contain 25 mg of exemestane. Each AROMASIN Tablet contains the following inactive ingredients: mannitol, crospovidone, polysorbate 80, hydroxypropyl methylcellulose, silicon dioxide, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, simethicone, polyethyleneglycol 6000, sucrose, magnesium carbonate, titanium dioxide, methyl-p-hydroxybenzoate, polyvinyl alcohol, cetyl esters wax, talc, carnauba wax, shellac and iron oxides.

PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name:	exemestane
Chemical Name:	6-methylenandrosta-1,4-diene-3,17-dione
Molecular Formula:	C ₂₀ H ₂₄ O ₂
Molecular Weight:	296.41
Structural Formula:	



Physical Form:	white to slightly yellow crystalline powder
Solubility:	freely soluble in N,N-dimethylformamide, soluble in methanol, and practically insoluble in water

CLINICAL TRIALS

Adjuvant Treatment of Early Breast Cancer:

The Intergroup Exemestane Study 031 (IES) was a randomized, double-blind, multicenter, multinational study comparing exemestane (25 mg/day) versus tamoxifen (20 or 30 mg/day) in postmenopausal women with early breast cancer. Patients, who remained disease-free after receiving adjuvant tamoxifen therapy for 2 to 3 years, were randomized to receive 3 to 2 years of AROMASIN or tamoxifen to complete a total of 5 years of hormonal therapy.

The primary objective of the study was to determine whether, in terms of disease-free survival (DFS), it was more effective to switch to AROMASIN rather than continuing tamoxifen therapy for the remainder of five years. Disease-free survival was defined as the time from randomization to time of local or distant recurrence of breast cancer, contralateral invasive breast cancer, or death from any cause.

The secondary objectives were to compare the two regimens in terms of overall survival, time to contralateral invasive breast cancer, breast cancer free survival, distant recurrence free survival, and long-term tolerability.

The principal analysis was planned to be carried out after 716 DFS events; three interim analyses were planned to take place during the study after 179, 358 and 537 events using nominal significance levels of 0.001, 0.004, 0.019, respectively, with the principal analysis undertaken using a nominal significance level of 0.043. However, the stopping boundary was crossed after the second analysis (which is therefore considered as the primary analysis) and the study results were released on the recommendation of the Independent Data Monitoring Committee (IDMC). Following release of these results and as it was agreed upon by the IDMC and the Steering Committee, an updated analysis was carried out when 95% of patients had at least 3 years of follow-up or had died during the corresponding period.

A total of 4724 patients in the intent-to-treat (ITT) analysis were randomized to AROMASIN (exemestane tablets) 25 mg once daily (N = 2352) or to continue to receive tamoxifen once daily at the same dose received before randomization (N = 2372). Demographics and baseline characteristics are presented in Table 5.

Table 5: Demographic and Baseline Characteristics from the IES Study of Postmenopausal Women with Early Breast Cancer (ITT Population)

Parameter	AROMASIN (N = 2352)	Tamoxifen (N = 2372)
Age (years):		
Median age (range)	63 (38 – 96)	63 (31 – 90)
Nodal status, n (%):		
Negative	1217 (51.7)	1230 (51.9)
Positive	1053 (44.8)	1045 (44.1)
1-3 Positive nodes	722 (30.7)	709 (29.9)
4-9 Positive nodes	241 (10.2)	245 (10.3)

Parameter	AROMASIN (N = 2352)	Tamoxifen (N = 2372)
>9 Positive nodes	87 (3.7)	85 (3.6)
Not reported	3 (0.1)	6 (0.3)
Unknown or missing	82 (3.5)	97 (4.1)
Histologic type, n (%):		
Infiltrating ductal	1777 (75.6)	1830 (77.2)
Infiltrating lobular	341 (14.5)	321 (13.5)
Other	231 (9.8)	214 (9.0)
Unknown or missing	3 (0.1)	9 (0.3)
Receptor status*, n (%):		
ER and PgR Positive	1341 (57.0)	1328 (56.0)
ER Positive and PgR Negative/Unknown	682 (29.0)	693 (29.2)
ER Unknown and PgR Positive**/Unknown	270 (11.5)	281 (11.9)
ER Negative and PgR Positive	6 (0.3)	8 (0.3)
ER Negative and PgR Negative/Unknown (none positive)	51 (2.2)	58 (2.4)
Missing	2 (0.1)	4 (0.2)
Tumor Size, n (%):		
≤ 0.5 cm	57 (2.4)	46 (1.9)
> 0.5 – 1.0 cm	315 (13.4)	302 (12.7)
> 1.0 – 2 cm	1032 (43.9)	1033 (43.5)
> 2.0 – 5.0 cm	832 (35.4)	884 (37.3)
> 5.0 cm	63 (2.7)	59 (2.5)
Not reported	53 (2.3)	48 (2.0)
Tumor Grade, n (%):		
G1	396 (16.8)	393 (16.6)
G2	978 (41.6)	1009 (42.5)
G3	454 (19.3)	427 (18.0)
G4	23 (1.0)	19 (0.8)
GX	56 (2.4)	47 (2.0)
Unknown/Not Assessed/Not reported	441 (18.8)	472 (19.9)
Type of surgery, n (%):		
Mastectomy	1231 (52.3)	1243 (52.4)
Breast-conserving	1117 (47.5)	1123 (47.3)
Unknown or missing	4 (0.2)	6 (0.3)
Radiotherapy to the breast, n (%):		
Yes	1524 (64.8)	1522 (64.2)
No	824 (35.5)	845 (35.6)
Not reported	4 (0.2)	5 (0.2)
Prior therapy, n (%):		
Chemotherapy	774 (32.9)	768 (32.4)
Hormone replacement therapy	565 (24.0)	559 (23.6)
Bisphosphonates	43 (1.8)	36 (1.5)
Duration of tamoxifen therapy at randomization (months):		
Median (range)	28.5 (15.8 – 52.2)	28.4 (15.6 – 63.0)
Tamoxifen dose, n (%):		
20 mg	2271 (96.6)	2290 (96.5)
30 mg	78 (3.3)	75 (3.2)
Not reported	3 (0.1)	7 (0.3)

* Results for receptor status include the results of the post-randomization testing of specimens from subjects for whom receptor status was unknown at randomization.

**Only one subject in the exemestane group had unknown ER status and positive PgR status.

Efficacy results of the primary analysis:

After a median duration of therapy of 27 months and with a median follow-up of 35 months, 519 events were reported, 213 in the AROMASIN group and 306 in the tamoxifen group (Table 6). This resulted in the conduct of the second interim analyses (analysis therefore considered as primary analysis) which crossed the stopping boundary and the study results were thus released.

Table 6: Primary Endpoint Events (ITT Population) at Primary Analysis

Event	First Events N (%)	
	AROMASIN (N = 2352)	Tamoxifen (N = 2372)
Loco-regional recurrence	34 (1.5)	45 (1.9)
Distant recurrence	125 (5.3)	179 (7.6)
Second primary – contralateral breast cancer	7 (0.3)	25 (1.1)
Death – breast cancer	1 (0.04)	8 (0.3)
Death – other reason	42 (1.8)	44 (1.9)
Death – missing/unknown	3 (0.1)	5 (0.2)
Ipsilateral breast cancer	1 (0.04)	0
Total number of events	213 (9.1)	306 (12.9)


The results of the primary analysis are shown in Table 7. The unadjusted hazard ratio in the AROMASIN group as compared to the tamoxifen group was 0.69 (nominal p= 0.00003; stopping boundary p=0.004), representing a 31% reduction in the risk of relapse in the observed study period. Overall survival was not significantly different in the two groups, with 116 deaths occurring in the AROMASIN group and 137 in the tamoxifen group.

Table 7: Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer at Primary Analysis

Endpoint	Population	Hazard Ratio (95% CI)	p-value (log-rank test)
Disease free survival	All patients	0.69 (0.58-0.82)	0.00003
	ER+ patients	0.65 (0.53-0.79)	0.00001
Breast cancer free survival*	All patients	0.65 (0.54-0.79)	<0.00001
	ER+ patients	0.58 (0.47-0.73)	<0.00001
Time to contralateral breast cancer	All patients	0.32 (0.15-0.72)	0.003
	ER+ patients	0.22 (0.08-0.57)	0.0007
Distant recurrence free survival	All patients	0.70 (0.56-0.86)	0.0008
	ER+ patients	0.65 (0.51-0.83)	0.0005
Overall survival	All patients	0.86 (0.67-1.10)	0.23
	ER+ patients	0.87 (0.66-1.16)	0.34

* In this analysis deaths of patients who did not have a recurrence or contralateral breast cancer were censored.

Figure 1: Disease Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (All patients) at Primary Analysis



Similar results were observed in the efficacy analyses adjusted for pre-specified prognostic factors and in most subsets of patients identified by baseline prognostic factors (i.e. ER status [positive or unknown], nodal status [negative, ≤ 3 positive nodes and > 3 positive nodes], prior chemotherapy and prior use of hormone replacement therapy).

Updated efficacy results (52 months):

In this updated analysis, 807 events were reported, 354 in the AROMASIN group and 453 in the tamoxifen group, after a median duration of therapy of 30 months and with a median follow-up of about 52 months (Table 8).

Table 8: Primary Endpoint Events (ITT Population) following Updated Analysis

Event	First Events N (%)	
	AROMASIN (N = 2352)	Tamoxifen (N = 2372)
Loco-regional recurrence	48 (2.0)	67 (2.8)
Distant recurrence	210 (8.9)	252 (10.6)
Second primary – contralateral breast cancer	18 (0.8)	35 (1.5)
Death – breast cancer	3 (0.1)	4 (0.2)
Death – other reason	65 (2.8)	80 (3.4)
Death – missing/unknown	9 (0.4)	15 (0.6)
Ipsilateral breast cancer	1 (0.04)	0
Total number of events	354(15.1)	453 (19.1)

The results of the updated analysis (52-month median follow-up) for the ITT population and estrogen receptor positive patients are shown in Table 9.


Table 9: Efficacy Results from the IES Study in Postmenopausal Women with Early Breast Cancer following Updated Analysis

Endpoint	Population	Hazard Ratio (95% CIs)	p-value (Log-rank test)
Disease free survival	All patients	0.76 (0.67-0.88)	0.0002
	ER+ patients	0.75 (0.65-0.88)	0.0003
Breast cancer free survival*	All patients	0.76 (0.65-0.89)	0.0004
	ER+ patients	0.73 (0.62-0.87)	0.0004
Time to contralateral breast cancer	All patients	0.57 (0.33-0.99)	0.04
	ER+ patients	0.54 (0.30-0.95)	0.03
Distant recurrence free survival	All patients	0.83 (0.70-0.98)	0.03
	ER+ patients	0.78 (0.65-0.95)	0.01
Overall survival	All patients	0.85 (0.71-1.02)	0.07
	ER+ patients	0.84 (0.68-1.02)	0.08

* In this analysis deaths of patients who did not have a recurrence or contralateral breast cancer were censored

In the whole study population AROMASIN reduced the risk of breast cancer recurrence by 24% compared with tamoxifen (hazard ratio 0.76, p =0.0002) (Figure 2).

Figure 2: Disease Free Survival in the IES Study of Postmenopausal Women with Early Breast Cancer (All patients) following Updated Analysis



Patients at Risk (Events)

Tamoxifen	2372 (66)	2270 (91)	2167 (82)	2056 (71)	1737 (62)	1144 (36)	807 (30)	376 (13)	71
Exemestane	2352 (48)	2257 (52)	2193 (62)	2102 (68)	1901 (61)	1211 (36)	839 (23)	395 (4)	64

The beneficial effect of AROMASIN over tamoxifen with respect to DFS was apparent regardless of nodal status or prior chemotherapy. Overall survival was not significantly different between the two groups, although a trend for improved overall survival was observed for AROMASIN (222 deaths) compared to tamoxifen (262 deaths) with a hazard ratio 0.85 (log-rank test: p=0.07), suggesting a 15% reduction in the risk of death in favor of AROMASIN.

Similar results were observed in the DFS and overall survival analyses adjusted for pre-specified prognostic factors and in most subsets of patients identified by baseline prognostic factors (i.e. ER status [positive or unknown], nodal status [negative, ≤ 3 positive nodes and >3 positive nodes], prior chemotherapy and prior use of hormone replacement therapy).

Updated analysis, performed after a median follow-up of 119 months, showed no significant difference in overall survival between the two groups, with 467 deaths (19.9%) occurring in the AROMASIN group and 510 deaths (21.5%) in the tamoxifen group. In this updated analysis of the whole study population, AROMASIN reduced the risk of breast cancer recurrence by 14% compared with tamoxifen (hazard ratio 0.86; p=0.004).

Treatment of Advanced Breast Cancer

a) Treatment After Antiestrogen Therapy:

AROMASIN Tablets 25 mg were evaluated in a Phase III, well-controlled, double-blind, multicenter, multinational, study and in two Phase II uncontrolled multicenter studies of postmenopausal women with advanced breast cancer who had disease progression after hormonal treatment with antiestrogens (primarily tamoxifen) for metastatic disease or as adjuvant therapy. In all studies, patients were required to have measurable metastases or lytic bone disease due to breast cancer, reasonable performance status (ECOG score = 0, 1, or 2), and near-normal organ function. Patients may also have received prior cytotoxic therapy, either for adjuvant or metastatic disease.

In all studies, the primary efficacy variable was objective response rate (complete response [CR] and partial response [PR]). Response rates were assessed based on World Health Organization (WHO) criteria. Objective responses in the Phase III study were submitted to an external blinded review.

Overall success rate (CR + PR + prolonged stable disease \geq 24 weeks), duration of response, duration of overall success, duration of prolonged stable disease, time to tumor progression, and time to treatment failure were also assessed. Subjective measurements of performance status and tumor-related signs and symptoms were assessed. The European Organization on Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) instrument was also utilized. In the Phase III study, survival was a secondary endpoint.

In the Phase III study, 769 patients were randomized to receive AROMASIN 25 mg once daily (N = 366) or megestrol acetate 40 mg four times daily (N = 403). In the two Phase II studies, 265 patients received AROMASIN 25 mg once daily. AROMASIN was administered soon after a light breakfast in all studies. Demographics and other baseline characteristics were similar for patients across studies. The median age of patients across studies was 65 years (range 30 to 99 years) and the majority of patients had disease-related functional impairment as evidenced by a performance status of 1 or 2. Approximately 70% of all patients were estrogen-receptor (ER) and/or progesterone-receptor (PgR) positive. The receptor status was unknown for about 25% of patients; about 20% of patients had previously responded to hormonal therapy. About 70% of all patients had measurable disease. The predominant site of disease was bone in about 30% of patients and soft tissue in about 14% of patients. Over half of all patients had visceral metastases. Demographic and baseline characteristics of patients receiving megestrol acetate in the Phase III study were similar to those of patients receiving AROMASIN.


Objective response rates ranging from 15% to 28% were achieved with AROMASIN 25 mg once daily in all three studies. The efficacy results from the Phase III study are shown in Table 10. The objective response rates observed in the two treatment arms were not statistically different (95% C.I, -7.5 to +2.3).

Table 10: Efficacy Results from a Phase III Study of Postmenopausal Women with Advanced Breast Cancer Whose Disease Had Progressed after Antiestrogen Therapy

Response Characteristics	AROMASIN (N=366)	Megestrol acetate (N=403)	p-value
Objective Response Rate = CR + PR (%) 95% Confidence Interval	15.0 (11.5-19.1)	12.4 (9.4-16.0)	
Overall Success = CR + PR + SD ≥ 24 Weeks (%) 95% Confidence Interval	37.4 (32.3-42.6)	34.6 (29.9-39.6)	
CR (%)	2.2	1.2	
PR (%)	12.8	11.2	
SD (%)	40.7	41.9	
SD ≥ 24 Weeks (%)	21.3	21.1	
PD (%)	35.0	36.2	
Other (%)*	9.3	9.4	
Median Duration of Response (weeks)	76.1	71.0	
Median Duration of Overall Success (weeks)	60.1	49.1	0.025
Median Duration of SD ≥ 24 Weeks (weeks)	48.0	46.6	
Median TTP (weeks)	20.3	16.6	0.037
Median TTF (weeks)	16.3	15.7	0.042
Median Overall Survival (weeks)	not reached	123.4	0.039
75% Survival (weeks)† 95% Confidence Interval	74.6 (59.1-91.0)	55.0 (46.1-70.3)	
*Includes patients who were not treated or not evaluable †25 th percentile Abbreviations: CR = complete response, PD = progressive disease, PR = partial response, SD = stable disease (no change), TTP = time to tumor progression, TTF = time to treatment failure			

Patients treated with AROMASIN had significantly longer duration of overall success, (p=0.025), time to tumor progression (p=0.037), and time to treatment failure (p=0.042) than those treated with megestrol acetate. Patient treated with AROMASIN also had a significantly longer duration of overall survival (p = 0.039). Because median survival was not yet reached for the patients treated with AROMASIN, the 75th survival (25th percentile) was calculated. The Kaplan-Meier curves for duration of overall success, time to tumor progression, and overall survival in the Phase III study are shown in Figures 3-5. The results in Figure 5 indicate an early separation of the survival curves resulting in a 19.4-week difference favoring AROMASIN (74.6 weeks versus 55.0 weeks).


Figure 3: Duration of Overall Success, (Complete plus Partial Responses plus Stable Disease ≥ 24 Weeks in a Phase III Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Antiestrogen Therapy



	Median Weeks (95% CI)	No. of patients with PD/No. patients	Log-rank <i>p</i> = 0.025
AROMASIN	60.1 (50.7 - 72.0)	74/133	
Megestrol Acetate	49.1 (45.4 - 61.0)	78/135	

PD: progressive disease


Figure 4: Time to Tumor Progression in a Phase III Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Antiestrogen Therapy



	Median Weeks (95% CI)	No. patients with PD/No. patients	Log-rank
AROMASIN	20.3 (16.1 - 24.7)	270/366	p = 0.037
Megestrol Acetate	16.6 (15.6 - 22.9)	305/403	

PD: progressive disease

Figure 5: Overall Survival in a Phase III Study of Postmenopausal Women With Advanced Breast Cancer Whose Disease Had Progressed After Antiestrogen Therapy



	Median Weeks (95% CI)	No. Deaths/No. Patients	Log-rank
AROMASIN	nr (122.1 – nr)	100/366	p = 0.039
Megestrol Acetate	123.4 (99.6 – nr)	130/403	

nr: Not reached at 123 weeks

In the Phase III study, three prognostic factors (prior antiestrogen treatment, prior chemotherapy, and site of metastasis), as well as the effect of protocol treatment, were examined as predictors of outcome in a protocol-defined Cox-regression analysis. The results indicate that treatment with AROMASIN was a favorable, predictive factor for time to tumor progression (odds ratio = 0.84; $p = 0.035$), time to treatment failure (odds ratio = 0.82; $p=0.023$), and overall survival (odds ratio = 0.77; $p=0.046$). These results indicate an approximate 20% exemestane-related reduction in risk for tumor progression and death, independent of response to prior antiestrogen treatment, extent of prior chemotherapy, and extent of visceral or other metastatic disease.

Tumor-related pain and other tumor-related signs and symptoms were prospectively measured and analyzed at baseline and during the study. A greater proportion of patients who responded to treatment with AROMASIN showed an improvement in tumor-related pain compared with those responding to megestrol acetate (51.4% versus 46.2%), and a greater proportion of all patients treated with AROMASIN showed an improvement in tumor-related signs and symptoms (12.1% versus 7.5%).

The European Organization on Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) instrument was also utilized. The 30 questions in the EORTC QLQ-C30 instrument were converted into 15 subscales. Patients receiving AROMASIN reported significantly better results than those receiving megestrol acetate for global health status ($p<0.001$), two of five functional scales (physical, role; $p<0.001$), and three of nine symptom scales (fatigue, dyspnea, and constipation; $p=0.001$). Patients receiving megestrol acetate noted significantly better results than patients receiving AROMASIN for one functional scale (emotional; $p=0.01$) and one symptom scale (appetite loss; $p<0.007$). An improvement in pain on both symptom scales was observed for both treatments, but was significantly improved for megestrol acetate ($p<0.007$). No significant differences were noted for the other subscales.

b) Treatment in Patients Whose Disease Has Progressed After Multiple Hormonal Therapies:

Three Phase II studies support the use of AROMASIN 25 mg once daily in postmenopausal patients with advanced breast cancer that has progressed after multiple hormonal therapies. A total of 419 women participated in these studies; previous treatment included antiestrogens, megestrol acetate, or reversible nonsteroidal aromatase inhibitors. The median age was 65 years (range 38 to 88 years), and the majority of patients had a performance status of 1 or 2. The majority (78.8%) of patients was ER and/or PgR positive. The receptor status was unknown in 20.5% of patients or negative in 0.7% of patients. Approximately 65% of the patients had measurable disease. The predominant site of disease was bone in 35.8% of patients and soft tissue in 11.5% of patients. Over half of the patients had visceral metastases.

AROMASIN 25 mg once daily induced objective response rates in 9% of patients and long-term disease stabilization of ≥ 24 weeks in another 17.5% of patients. No benefit was seen in escalating the dose of AROMASIN to 100 mg in patients who progressed while receiving AROMASIN 25 mg once daily.

Subjective responses of tumor-related pain, other tumor-related signs and symptoms, and the EORTC-QLQ C30 were prospectively measured and analyzed. There was an improvement compared with baseline in the tumor-related pain score in 28.6% of responding patients and in 22.9% of patients experiencing a long-lasting stable disease (≥ 24 weeks) and an improvement compared with baseline in the other tumor-related signs and symptoms in 30.6% of patients with an objective response and in 9.6% of patients with a long-term stable disease. The EORTC QLQ-C30 scores after treatment were not significantly different from baseline.

Comparative Bioavailability Studies:

Absolute bioavailability could not be determined in humans due to the absence of a suitable intravenous formulation. Preclinical data obtained in rats and dogs in which exemestane was administered intravenously (formulated in polypropylene glycol and saline, 50:50, v/v), indicated that the absolute bioavailability was approximately 5%. Since most of the DRM was found to be absorbed following oral dosing, the observed low bioavailability could be attributed to an extensive first-pass elimination. First-pass metabolism also probably occurs in humans, since the plasma levels of total radioactivity were much higher than those of the intact drug even at the first sampling times. In clinical pharmacokinetic studies, exemestane was administered as hard gelatin capsule, sugar coated tablet, or as a suspension. All formulations utilized micronized active ingredient. The different formulations gave similar pharmacokinetic profiles in terms of rate and extent of absorption. Tablets and capsules showed the same concentration-time profile and they were shown to be bioequivalent. The average relative bioavailability of tablets versus suspension was found to be 86%; the results from this study demonstrated the adequacy of the solid dosage form and suggested that absorption of exemestane was not dissolution-rate limiting. A significant increase (approximately 39%) in the systemic exposure (area under the curve, AUC) was observed when tablets were administered after a high-fat breakfast compared with the same formulation administered under fasting conditions. As a result, in clinical practice it is recommended that exemestane be administered with food (preferably after a meal).

DETAILED PHARMACOLOGY

Preclinical Pharmacology:

Exemestane is an irreversible, steroidal aromatase inactivator, structurally related to the natural substrate androstenedione. It acts as a false substrate for the aromatase enzyme, and is processed to an intermediate that binds irreversibly to the active site of the enzyme causing its inactivation, an effect also known as “suicide inhibition.” *De novo* aromatase enzyme synthesis is required for recovery of enzyme activity. Exemestane significantly lowers circulating estrogen concentrations in postmenopausal women, but has no detectable effect on adrenal biosynthesis of corticosteroids or aldosterone. Exemestane has no effect on other enzymes involved in the steroidogenic pathway up to a concentration at least 600 times higher than that inhibiting the aromatase enzyme.

***In vitro* studies and mechanism of action:**

In *in vitro* studies with various preparations of human placental aromatase, exemestane was found to inhibit the conversion of androstenedione to estrogens with an IC₅₀ ranging from 25.4 to 45 nM. Exemestane showed 1-3 times more potent aromatase inhibition than formestane (IC₅₀ ranging from 21.9 to 85 nM) and approximately a hundred times more potent aromatase inhibition than aminoglutethimide (IC₅₀ ranging between 1,750 and 3,800 nM).

Exemestane was found to be very effective in inhibiting aromatase activity of MCF-7 breast cancer cell lines (IC₅₀ 32.9 nM), human breast tumors (IC₅₀ 12.2 nM) or cultured fibroblasts of human breast adipose tissue (IC₅₀ 5.3 nM). In the cultured breast fibroblasts exemestane was found to be 3 times more potent than anastrozole.

Exemestane was also found to be 2 or 4 times more potent than formestane or aminoglutethimide in inhibiting rat ovarian aromatase.

The major metabolites of exemestane were much less potent inhibitors of the human placental aromatase than exemestane itself. The most potent metabolite was 17-hydroexemestane (FCE 25071), which however was 2.6 fold less potent than exemestane.

The inactivation of human placental enzyme by exemestane was of the competitive type (K_i of 4.3 nM or 1.3 ng/mL, compared to a K_m of 11 nM for the substrate androstenedione).

The pre-incubation of human placental aromatase with exemestane before adding the substrate caused a time-dependent inhibition (*i.e.*, inactivation) of the enzyme, as occurs for formestane. It was also found that inactivation of human placental aromatase by exemestane required the presence of the cofactor NADPH, suggesting that exemestane exerted a mechanism-based inactivation effect on human placental aromatase, as reported for formestane.

***In vivo* studies:**

Aromatase inactivation by exemestane was observed *in vivo* in pregnant mare's serum gonadotropin (PMSG)-primed adult rats. Twenty-four hours after a single treatment exemestane was found to be very potent in reducing ovarian aromatase activity by both the subcutaneous and the oral routes, showing ED₅₀ values of 1.8 and 3.7 mg/kg, respectively. The decrease in ovarian aromatase caused by exemestane in PMSG-primed rats was coupled to a parallel decrease in plasma estradiol levels.

The antitumor activity of exemestane was assessed in ovariectomized rats with dimethylbenzanthracene (DMBA)-induced mammary tumors, maintained with testosterone propionate (TP), a "postmenopausal" tumor model in which extra-ovarian aromatization of circulating androgens is the main source of estrogens. In this "postmenopausal" tumor model exemestane exhibited antitumor activity starting from 0.3 mg/kg/day p.o. and at 10 mg/kg/day s.c. (the lowest dose tested by this route). The number of new tumors was also reduced by exemestane. In addition, the regression of tumor growth caused by ovariectomy in tumor-bearing rats was not influenced by exemestane (50 mg/kg/day s.c.), thus indicating that the compound and its metabolites did not have any intrinsic estrogenic effect (*i.e.*, no tumor stimulating effect).

In a “premenopausal” model, in which intact cycling rats had DMBA-induced mammary tumors, exemestane inhibited tumor growth by 44% and 70% at s.c. doses of 3 and 10 mg/kg/day, respectively. Ovarian aromatase activity was suppressed ($\geq 96\%$) at 10 mg/kg/day. Doses higher than 10 mg/kg/day s.c. provided no additional inhibition of tumor growth. No activity or very low activity was observed with oral doses up to 100-200 mg/kg/day.

In intact rats with DMBA-induced mammary tumors, the combined treatment with exemestane (20 mg/kg/day s.c.) and the antiestrogen tamoxifen (1 mg/kg/day p.o.) resulted in higher antitumor effect than either treatment alone. The combination of exemestane (50 mg/kg/day s.c.) with the prolactin-lowering drug cabergoline (0.2 mg/kg/day p.o.) was also more effective than either treatment alone.

In the mouse, there was no effect on either locomotor activity or hexobarbital sleeping time at doses up to 100 mg/kg. At 100-200 mg/kg there was slight irritability and increased tail-pinch response. Reduced spontaneous motor activity and respiratory depression, tremors and clonus were observed at 400-800 mg/kg. Hypothermia was seen at doses above 400 mg/kg and death attributed to respiratory depression occurred starting from 800 mg/kg. Exemestane (400 mg/kg) had a pro-convulsive effect when given prior to a subthreshold dose of pentylenetetrazole (PTZ). Doses below 100 mg/kg had no effect on the seizures or mortality induced by PTZ or electroshock in the mouse.

In rats, as in mice, there was a slight behavioral depression at doses of 400-1600 mg/kg but there were no effects on body temperature and no mortality up to 1600 mg/kg. Single doses up to 100 mg/kg had no effect on rotarod performance and 100 mg/kg exemestane, given in twice daily doses for four consecutive days did not affect pentobarbital sleep time.

In dogs anesthetized with pentobarbital, single intraduodenal doses of exemestane up to 100 mg/kg produced no noteworthy effects on the cardiovascular or respiratory systems and did not affect the responses to norepinephrine, acetylcholine, isoproterenol, histamine or carotid occlusion. Oral doses up to 100 mg/kg of exemestane, given once or daily for 5 days did not affect gastrointestinal transit time or produce changes in the gastric mucosa in rats or mice. There was no effect on gastric acid secretion at doses up to 100 mg/kg in the pyloric-ligated rat. Biliary secretion was unaffected by single doses of exemestane in the rat, but there was a 24-29% increase in choleresis following doses of 100 mg/kg daily for 5 days.

Neither urinary volume nor electrolyte excretion were affected at doses up to 1,000 mg/kg in the rat.

Exemestane was devoid of estrogenic, antiestrogenic, progestational, antiprogestational, glucocorticoid and antiglucocorticoid activity at s.c. or oral doses up to 100 mg/kg in the rat or rabbit. However exemestane exhibited a weak androgenic and anabolic activity at 3-10 mg/kg/day s.c. and 100 mg/kg/day p.o. in the rat.

Adrenocorticotrophic-hormone (ACTH)-stimulated corticosterone secretion in rats was not affected by doses of exemestane of up to 300 mg/kg/day p.o., indicating that *in vivo* the compound did not inhibit the various hydroxylases involved in the synthesis of corticosteroids.

In guinea pigs sensitized with exemestane, given orally or subcutaneously at 20 mg/kg, three times every second day, no antigenicity was found.

Clinical Pharmacology:

Pharmacodynamics:

Exemestane is a potent aromatase inactivator, causing estrogen suppression and inactivation of peripheral aromatisation.

In healthy postmenopausal woman, single oral doses of exemestane (studies 001, 008, 012, 023) caused a dose-dependent decrease in circulating estrogens. At the dose of 0.5 mg of exemestane, estrogen suppression was very limited (~10-25% inhibition), whereas maximal suppression was observed at the dose of 25 mg (~70% for all estrogens). At the recommended dose of 25 mg, maximal estrogen suppression was observed 2-3 days after dosing. It was very long lasting, as estrogen levels recovered to baseline 10-14 days after dosing.

In postmenopausal breast cancer patients, maximal estrogen suppression was generally observed at doses of 10-25 mg daily (85-95%). In both Phase II and III studies, estrogen suppression was found to be still present to the same degree at the time of disease progression, thus indicating that loss of activity was not due to loss of pharmacodynamic effect, but to newly developed tumor resistance, that might also include an acquired hypersensitivity of some tumor cells to estrogens.

After 6-8 weeks of exemestane 25 mg/day, whole body aromatization was reduced by 97.9%.

In order to determine the specificity of exemestane's action, the effect of the drug on circulating hormones other than estrogen was studied. No effect on any of the tested hormones was observed after single exemestane doses. After repeated doses, a dose-related decrease in sex-hormone binding globulin (SHBG) and a non dose-related increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH) levels were observed. The decrease in SHBG (21% to 49% at 25 mg/day) is very likely related to the androgenic effect of exemestane and/or its metabolite 17-hydroexemestane, exerted at the level of the liver where this hormone is produced. The slight increase in LH and FSH levels (29% and 45% at 25 mg/day) is probably due to a compensatory feed-back mechanism resulting from the marked reduction in circulating estrogens. Exemestane 25 mg daily had no significant effect on thyroid function [free triiodothyronine (FT3), free thyroxine (FT4) and thyroid stimulating hormone (TSH)].

TOXICOLOGY

Acute toxicity:

The acute toxicity of exemestane was characterized in single oral dose studies in mice, rats and dogs. The oral LD₅₀ of exemestane was greater than 3000 mg/kg in mice and above 5000 mg/kg in rats. The LD₅₀ was approximately 400 mg/kg in mice when given by the i.p. route. In male rats, the i.p. LD₅₀ was 488 mg/kg and in females, 404 mg/kg. The clinical signs in these acute studies in the rodent included sedation, dyspnea, staggering gait, prostration and convulsions.

Exemestane had no noteworthy effects at a single oral dose of 1000 mg/kg in dogs; however, at higher doses it caused death in females which was preceded by congestion and erosions in the gastrointestinal tract. Vomiting, ataxia, muscular tremors, sedation and convulsions were also seen at these higher doses. These observations correlate well with the findings recorded in general pharmacology tests, in which signs of CNS stimulation were observed in rats and mice while convulsions occurred in mice from the dose of 800 mg/kg.

Long-term toxicity:

The long-term toxicity of exemestane was assessed in repeat dose studies in the mice, rats, and dogs.

Mouse:

A 13-week toxicity study was performed in mice administering exemestane at the doses of 30, 100, 350 and 1250 mg/kg/day by diet as dose-range finding for a future carcinogenicity test. No mortality or clinical signs were seen at any dose. The organs most affected were the liver, kidneys and reproductive organs. The main findings were: in the liver, enlargement and hypertrophy of the hepatocytes; in the kidneys, tubulo-epithelial hyperplasia; in the reproductive organs, reduction in size of seminal vesicles and prostate, absence of corpora lutea and presence of atretic follicles with a corresponding minimal stromal hyperplasia in the ovaries and stromal hypoplasia in the uterus.

Rat:

A 4-week toxicity study was performed in rats at the doses of 30, 150, 750 and 3750 mg/kg/day. At the highest dose there was 100% mortality within the first two weeks in both sexes. At the dose of 750 mg/kg/day only minor changes in laboratory parameters and at necropsy in some organ weights (increase in liver and decrease in adrenal and prostatic weights) were observed. For these reasons an additional study was performed in rats administering exemestane for 4 weeks at the doses of 1000 and 2000 mg/kg/day. If the results of these studies are evaluated together, there is a clear dose-related effect as far as mortality, involvement of the liver, kidney, lymphoid tissues and reproductive organs are concerned. The major findings were: in the liver, increase in hepatic enzymes and enlargement at necropsy; in the kidneys, necrosis in the tubular epithelium of the cortex; in the reproductive organs, reduced spermatogenesis, reduced secretion in the prostate and seminal vesicles, follicular cysts in the ovaries and mucin secreting epithelium in the vagina.

Exemestane was administered orally at the doses of 30, 180 and 1080 mg/kg/day for 26 weeks and at the doses of 20, 50, 125 and 315 mg/kg/day for 52 weeks. If the results of both studies are evaluated together, the main target organ was the liver. Clear hepatic changes, mainly consisting of vacuolation, hypertrophy and, at the dose of 1080 mg/kg/day, focal necrosis of hepatocytes were noted in the six-month study. After one-year administration there were signs of hepatic involvement, namely changes in laboratory parameters including coagulation time, proteins, alanino aminotransferase and alkaline phosphatase at 315 mg/kg/day and liver enlargement starting from 125 mg/kg/day, without any histological changes. The increase in alkaline phosphatase was attributed to liver lesions. Another target organ was the kidney. A chronic tubular nephropathy occurred in rats at the dose of 315 mg/kg/day in the 52-week toxicity study. This focal change, already observed in the 4-week study proved to be reversible. In the 26-week

study the vagina at all dose levels and uterine cervix at the high dose showed mucoid hyperplasia of the epithelium. The dose of 50 mg/kg/day was well tolerated; this dose is high enough to ensure an adequate safety index, taking into account that the ED₅₀ in the same species is 3.7 mg/kg (reduction of ovarian aromatase activity).

Dog:

Exemestane was administered for 4 weeks in dogs at the doses of 30, 90, 270 and 810 mg/kg/day. Some drug-related findings were observed in all dose groups. These changes consisted of a slight increase in liver weight and effects on the reproductive organs considered related to the pharmacological activity of exemestane such as hyperplasia of interstitial cells of the testes and follicular cysts in the ovaries. Therefore no toxic findings were found in dogs at any dose in this study. However, the chronic studies were able to define target organs and other functional changes.

Exemestane was administered to dogs of both sexes at the doses of 30, 150 and 750 mg/kg/day for 26 weeks and only to female dogs at the doses of 30, 120 and 480 mg/kg/day for one year (this is justified given the proposed indication). The compound induced signs of CNS stimulation including sporadic tremors and convulsions in some females during the first days of treatment at 750 mg/kg/day in the 26-week toxicity study. The main target organ was the liver, as in rodents. Functional changes occurred after six months and after one-year treatment they were associated with histological findings of biliary proliferation and epithelial hyperplasia of the gall bladder. All these changes regressed over the recovery period of six weeks. Hyperplasia of the interstitial cells of the testes, cysts and prominent secondary follicles in the ovary were found in the 26-week study. There was also a reversible inhibition of the normal estrous cycles. The no-toxic-effect level after one-year treatment in dogs was 30 mg/kg/day. At the oral dose of 30 mg/kg/day, the NOEL after one year treatment gave a safety margin of 6 when compared to that obtained in humans at the standard dose of 25 mg/day.

Carcinogenicity:

In a two-year carcinogenicity study in female rats, no treatment-related tumors were observed. In male rats the study was terminated on Week 92, because of early death by chronic nephropathy. There was no evidence of carcinogenic activity in male rats. At the highest dose evaluated in these studies, 315 mg/kg/day, plasma AUC_{0-24hr} levels in male and female rats were 34 and 56 times higher, respectively, than those measured in post-menopausal volunteers at the recommended dose.

In a two-year carcinogenicity study in mice, an increase in the incidence of hepatic neoplasms in both genders was observed at the intermediate and high doses (150 and 450 mg/kg/day). This finding is considered to be related to the induction of hepatic microsomal enzymes, an effect observed in mice but not in clinical studies. An increase in the incidence of renal tubular adenomas was observed in male mice at the high dose of 450 mg/kg/day. This change was considered to be species- and gender-specific and occurred at a dose that represents 63-fold greater exposure than occurs at the human therapeutic dose (see **WARNINGS AND PRECAUTIONS**).

Mutagenicity:

Exemestane, was not mutagenic in tests with *Salmonella typhimurium*, *Escherichia coli* or the V79 hamster cell line. It was also negative in the DNA repair test using rat hepatocyte primary cultures and in two in vivo tests, the micronucleus test and the chromosomal aberration test in mouse bone marrow cells. Exemestane was found to be positive only in the in vitro chromosome aberration test in human lymphocytes without metabolic activation: it was, however, negative in the same test after activation.

Reproduction and Teratology:

A fertility study was performed in female rats at the doses of 4, 20, and 100 mg/kg/day. The NOEL for reproductive performance and for the development of the offspring was 4 mg/kg/day. Higher doses induced reduced maternal body weight, delivery complications, prolonged gestation and deaths. At the two highest doses there was a reduction in fetal body weight, an increased incidence of retarded fetal ossification and a reduction in live litter size.

Exemestane was administered to rats at the doses of 10, 50, 250 and 810 mg/kg/day from Day 6 to Day 17 of pregnancy. The compound was not teratogenic up to the dose of 810 mg/kg/day. Among the rats that were allowed to litter there was, at all dose levels, an increased duration of gestation with consequent delivery complications in some animals and maternal death. This effect on gestation and delivery was expected in view of the pharmacological activity of the compound. A reduction in the number of live pups and live litter size was observed at doses of 50 mg/kg/day and above. Sex distribution, sex maturation and reproductive performance of offspring were not affected.

Exemestane was not teratogenic up to the dose of 270 mg/kg/day in rabbits. In terms of maternal toxicity in rabbits, the NOEL was 30 mg/kg/day because at higher doses there was a reduction in maternal body weight and food consumption. At 270 mg/kg/day there was a marked reduction in fetal body weight and in the number of live fetuses. The NOEL for embryofetal development was 90 mg/kg/day.

REFERENCES

1. Arkhipov A, Tiffany JK, Whaley FS, Miller LL, di Salle E, Ornati G, et al. Antitumor efficacy of FCE 24304 (exemestane [PNU 155971]) as third-line hormonal therapy in the treatment of postmenopausal women with metastatic breast cancer refractory to tamoxifen and Megace™. (Final Report of the Trial 120003-999) Pharmacia & Upjohn Internal Report PNU-155971/9850171; July 10, 1998
2. Arkhipov A, Tiffany JK, Whaley FS, Miller LL, di Salle E, Ornati G, et al. Efficacy trial of FCE 24304 (Exemestane, 6-methylenandrosta-1,4-diene-3,17-dione) in the treatment of postmenopausal patients with metastatic breast cancer failing tamoxifen. (Final Report of the Trial 120002-999). Pharmacia & Upjohn Internal Report PNU-155971/ 9850170; August 6, 1998.
3. Arkhipov A, Royer M, Tiffany JK, Whaley FS, Miller LL, diSalle E, et al. Antitumor efficacy of exemestane in postmenopausal women with metastatic breast cancer failing Tamoxifen and Megace (Interim Report of the Trial 95OEXE022). Pharmacia & Upjohn Internal Report PNU-155971/9850172, October 19, 1998.
4. Brodie A.M.H. and Njar V.C.O. Aromatase inhibitors and breast cancer. *Seminars in Oncology* 1996; 23/ 4 (Suppl.9): 10-20.
5. Colajori E, Carpentieri M, Polli A. Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen. Pharmacia/Pfizer Internal Report 96-OEXE-031-SR, October 18, 2004.
6. Carpentieri M, Polli A. Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen. Interim Full Clinical Study Report, Protocol A5991012; 96-OEXE-031(52-month median follow-up), October 16, 2006.
7. Carpentieri M, Polli A. Randomized double-blind trial in postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years, comparing subsequent adjuvant exemestane treatment with further tamoxifen – Bone Sub-study (Full Report up to 24 months on treatment). Protocol A5991012; 96-OEXE-031, September 11, 2006.
8. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. *N Engl J Med* 2004; 350: 1081-1092.
9. di Salle E, Giudici D, Briatico G, Ornati G: Novel irreversible aromatase inhibitors. *Ann NY Acad Sci* 1990;595:357-367.

10. di Salle E, Briatico G, Giudici D, Ornati G, Zaccheo T, Buzzetti F, et al. Novel aromatase and 5 alpha-reductase inhibitors. *J Steroid Biochem Molec Biol* 1994; 49: 289-294.
11. Fowst C, Polli A, Massimini G, di Salle E, Arkhipov A, et al. Antitumor efficacy of exemestane in postmenopausal patients with metastatic breast cancer, failing non-steroidal aromatase inhibitors. (Final Report of the Trial 94-OEXE 017) Pharmacia & Upjohn Internal Report PNU-155971/9850169 August 24, 1998.
12. Fowst C, Polli A, di Salle E, Massimini G, Mariani O, Arkhipov A, Gaylor S. Exemestane versus Megestrol acetate in postmenopausal patients with metastatic breast cancer, failing tamoxifen: a phase III, double-blind, randomized, parallel group, comparative study (Trial 94-OEXE-018). Pharmacia & Upjohn Internal Report PNU-155971/9850243; October 1998.
13. Giudici D, Ornati G, Briatico G, Buzzetti F, Lombardi P, Di Salle E. 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. *J. Steroid Biochem.* 1988; 30: 391-394.
14. Howard M. In vitro studies to determine the potential inhibition of human drug metabolising cytochromes P450 by exemestane (PNU 155971), letrozole (PNU 191826) and anastrozole (PNU 192331). Pharmacia & Upjohn Internal Report PNU-155971/9850104; September 1998.
15. Jannuzzo MG, Spinelli R. The effect of varying degrees of renal impairment on the pharmacokinetics of exemestane in postmenopausal volunteers: preliminary results. (Trial 95 OEXE 016). *Pharmacia & Upjohn Internal Preliminary Report PNU-155971/9850135*; February, 1998 + Amendment of Sept 10, 1998 (Report No. 9850240)
16. Jannuzzo MG, Spinelli R, Fiorentini F. The effect of varying degrees of hepatic impairment on the pharmacokinetics of exemestane in postmenopausal volunteers: preliminary results. (Trial 95 OEXE 015). *Pharmacia & Upjohn Internal Report PNU-155971/9850134*; February, 1998.
17. Jannuzzo MG, Spinelli R: The effect of varying degrees of renal impairment on the pharmacokinetics of exemestane in postmenopausal volunteers: preliminary results. (Trial 95 OEXE 016). *Pharmacia & Upjohn Internal Preliminary Report PNU-155971/9850135*; February 1998 + Amendment of Sept 10, 1998/950240.
18. Jannuzzo MG, Sarapa N, Polli A, Poggesi I, Rocchetti M, Spinelli R. A study to investigate a possible pharmacokinetic interaction between a single oral dose of exemestane 25-mg tablets and reifampicin 600 mg daily administered for two weeks to healthy postmenopausal women. *Pharmacia & Upjohn Internal Report 971-ONC-0028-076*; 5 September 2001.

19. Jannuzzo MG, Sinelli R, Poggesi I, Rocchetti M. Addendum I: “Additional pharmacokinetic and pharmacodynamic analyses” To study report: A study to investigate a possible pharmacokinetic interaction between a single oral dose of exemestane 25-mg tablets and reifampicin 600 mg daily administered for two weeks to healthy postmenopausal women. Addendum I to Pharmacia & Upjohn Internal Report 971-ONC-0028-076; 28 February 2002.
Appendix 1: Pouwels ADAJ, van Tilburg LP, Kok PR. Determination of metabolite PNU-152816 in human plasma samples obtained during clinical study 971-ONC-0028-076. Pharma Bioanalytical Report PBR-12433. January 29, 2002.
Appendix 2: Millérioux L, Guyonnet C. Analysis of estrone sulfate in plasma samples collected during the study: A study to investigate a possible pharmacokinetic interaction between a single oral dose of exemestane 25-mg tablets and reifampicin 600 mg daily administered for two weeks to healthy postmenopausal women. Pharmacia Protocol 971-ONC-0028-076. February 4, 2002.
20. Le Coz F, Jannuzzo MG, Poggesi I, di Salle E, Piscitelli G, Rocchetti M, et al. Study of the relative bioavailability and of the effect of food on the pharmacokinetics of exemestane in healthy postmenopausal volunteers. (Final report of the study 94-OEXE 012). *Pharmacia & Upjohn Internal Report PNU-155971/9650298*; May, 1997.
21. Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. *J Clin Oncol* 2005; 23: 5126-5137.
22. Massimini G, Polli A, Mariani O, di Salle E. Antitumor efficacy of exemestane in postmenopausal patients with metastatic breast cancer, failing to tamoxifen. (Final Report of the Study 93OEXE010). Pharmacia & Upjohn Internal Report PNU-155971/ 9850244, August 18, 1998.
23. Massimini G, Colajori E, Polli A, Paolini J. A randomized feasibility study of exemestane in postmenopausal breast cancer patients – low risk. Pharmacia/Pfizer Internal Report 95-OEXE-027-SR, August 20, 2004.
24. Pacciarini MA, Piscitelli G. Endocrinological evaluation of exemestane (PNU-155971; FCE 24304) in post menopausal patients with metastatic breast cancer receiving different doses. (Final report of the study 91-OEXE 007). *Pharmacia & Upjohn Internal Report PNU-155971/9650095*; September, 1997.+ Amendment of June 25, 1998 (Report N. 9850236)
25. Pichard L. Identification of the form(s) of cytochrome(s) P450 involved in the oxidative metabolism of FCE 24304 in human liver. *Pharmacia & Upjohn Internal Report PNU-155971/9750052*; January 1997.

26. Thébault JJ, Piscitelli G, di Salle E, Frevola L, Poggesi I, Polli A, Ornati G. Pharmacodynamics and Pharmacokinetics of Repeated Low Doses of Exemestane as Sugar-Coated Tablets in Healthy Postmenopausal Volunteers. (Final report of the study MIEXEPHDY019). *Pharmacia & Upjohn Internal Report PNU-155971/9750145*; September 19, 1997.

PART III: CONSUMER INFORMATION**AROMASIN**
exemestane

This leaflet is part III of a three-part "Product Monograph" published when AROMASIN was approved for sale in Canada and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about AROMASIN. Contact your doctor or pharmacist if you have any questions about the drug.

Keep this leaflet with your medicine; you may wish to refer to it again.

REMEMBER: This medicine is for your current medical condition only. Do not give it to others.

ABOUT THIS MEDICATION**What the medication is used for:**

AROMASIN is used for the adjuvant treatment of early breast cancer in postmenopausal women who had been treated previously with tamoxifen for 2 to 3 years.

AROMASIN is also used to treat advanced breast cancer in postmenopausal women who had been treated previously with antiestrogens (for example, tamoxifen).

Adjuvant means "in addition to". In early breast cancer, this means that additional treatment is required after primary treatment. The reason for this is that after surgery, a small number of cancer cells may remain in the body. These cells can continue to multiply and spread. Adjuvant therapy is given to prevent or delay these cells from multiplying and spreading. Cytotoxic chemotherapy, radiation, and hormonal treatment are three common forms of adjuvant treatment.

What it does:

AROMASIN interferes with a substance called aromatase which is needed to make the female sex hormone, estrogen, especially in postmenopausal women. AROMASIN reduces the amount of estrogen in the body. This is helpful because estrogen may influence the growth of certain types of breast cancer cells.

When the medication should not be used:

If you are allergic to exemestane or any other ingredient in AROMASIN tablets.

What the medicinal ingredient is:

The active ingredient is exemestane.

What the nonmedicinal ingredients are:

Mannitol, crospovidone, polysorbate 80, hydroxypropyl methylcellulose, silicon dioxide, microcrystalline cellulose,

sodium starch glycolate, magnesium stearate, simethicone, polyethyleneglycol 6000, sucrose, magnesium carbonate, titanium dioxide, methyl-p-hydroxybenzoate, polyvinyl alcohol, cetyl esters wax, talc, carnauba wax, shellac and iron oxides.

What dosage forms it comes in:

AROMASIN is available in tablets. Each tablet contains 25 mg of exemestane. The tablets are round and off-white to slightly gray in color.

WARNINGS AND PRECAUTIONS**Serious Warnings and Precautions**

AROMASIN is not recommended in pre-menopausal women as safety and efficacy have not been established in this group of patients.

The use of estrogen lowering agents, including AROMASIN, may cause bone loss. Women with osteoporosis (brittle bones), or at high risk of osteoporosis should be carefully monitored by their doctor. These women may require treatment for osteoporosis or treatment to prevent osteoporosis while receiving AROMASIN.

AROMASIN should be administered under the supervision of a qualified physician experienced in the use of anti-cancer agents.

The use of aromatase inhibitors, including AROMASIN, may increase the risk of ischemic cardiovascular diseases, such as heart attacks and angina. Women at risk of heart disease should be carefully monitored by their doctor.

The use of aromatase inhibitors, including AROMASIN, may increase the occurrence of high cholesterol. Your physician should continue his/her routine practice of checking lipid and cholesterol levels on a regular basis.

BEFORE you use AROMASIN talk to your doctor or pharmacist:

- If you have previously had an allergic reaction to exemestane or any of the other ingredients of AROMASIN (listed above).
- If you are still having your period
- If you are pregnant or likely to be pregnant or breast-feeding.
- If you are taking AROMASIN and have been prescribed hormone replacement therapy (HRT) or estrogens, you should discuss this with your doctor.
- If you have or have had kidney or liver disease
- If you have or have had cardiovascular or heart disease including any of the following: heart attack, stroke or uncontrolled blood pressure
- If you have or have had high cholesterol
- If you have been diagnosed with osteoporosis or have had a bone fracture related to osteoporosis because this medication may cause bone loss.

If you feel drowsy, dizzy or weak while taking AROMASIN, **do not** drive or operate machinery.

If you need to go into hospital while taking AROMASIN, let the doctor know about your medication.

INTERACTIONS WITH THIS MEDICATION

If you are taking tamoxifen and warfarin and switch to exemestane, your warfarin dose may need to be adjusted.

Taking other medications:

AROMASIN and other medication may affect each other. Inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed by a doctor, including non-prescription drugs or herbal medicines. During treatment do not start taking any new medicine without checking first with your doctor or pharmacist.

PROPER USE OF THIS MEDICATION

Usual dose:

Your doctor will discuss with you how long you will take AROMASIN.

The recommended dose is one 25 mg tablet, once daily, by mouth. The tablet should be taken with food (preferably after a meal). Try to take your tablet at the same time each day.

Overdose:

In case of drug overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

If too many tablets are taken by accident, contact your doctor at once, go to the nearest hospital or call a local poison control centre.

Missed Dose:

If you forget to take a dose of AROMASIN, don't worry; take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and go back to your regular dosage schedule. Do not double dose.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

AROMASIN, like all other medicines, may cause unwanted effects in some people.

Many women can take AROMASIN without any problems, but some women may have mild to moderate side effects. If you have any of the following side effects, tell your doctor or pharmacist as soon as possible.

Very common side effects (they affect more than 10 in every 100 patients)

- Hot flushes
- Nausea
- Fatigue
- Dizziness
- Pain in bones and joints (arthralgia)
- Depression
- Excessive sweating
- Headache
- Abdominal pain

Common side effects (they affect between 1 to 10 in every 100 patients)

- Bone loss (osteoporosis)
- Bone fractures
- Sleeplessness
- Skin rash
- Increase of appetite
- Muscle and joint pain
- Constipation
- Weight gain
- Hair loss
- Diarrhea
- Excess fluid usually in the legs
- Indigestion
- High blood pressure
- High cholesterol
- Pain or burning sensation in the hands or wrists (carpal tunnel syndrome)
- Hives
- Itchiness
- Infections of the urinary tract
- Abnormal liver function test results (blood test disorders)

Uncommon side effects (they affect between 1 to 10 in every 1000 patients)

- Hypersensitivity (including anaphylactic reaction)
- Burning stomach pain, heart burn, nausea or vomiting that could progress to blood in stools, black tarry stools or vomiting of blood (gastric ulcers)
- Nerve damage with symptoms such as pain, burning, or numbness (neuropathy)

SERIOUS SIDE EFFECTS, HOW OFTEN THEY HAPPEN AND WHAT TO DO ABOUT THEM

Symptom / effect	Talk with your doctor or pharmacist		Stop taking drug and call your doctor or pharmacist
	Only if severe	In all cases	
Common			
Pain in muscles, bones and joints	√		
Vaginal Bleeding		√	
Uncommon			
Chest Pain in association with shortness of breath and sensation of fullness/heaviness		√	√
Burning stomach pain, heart burn, nausea or vomiting that could progress to blood in stools, black tarry stools or vomiting of blood (gastric ulcer)		√	√
Hypersensitivity (including anaphylactic reactions)		√	√
Rare			
Allergic Reaction (skin rash/swelling/difficulty breathing)			√
Yellowing of the skin or eyes, nausea, loss of appetite, dark-coloured urine (signs of hepatitis)		√	√

This is not a complete list of side effects. For any unexpected effects while taking AROMASIN, contact your doctor or pharmacist.

HOW TO STORE IT

- Keep them in the original package and store them at 15-30°C. Avoid places where the temperature may rise above 30°C.
- Keep this medicine out of the reach of children.
- Before use, check the expiry date printed on the pack. Do not use after this date. Remember to take any unused medication back to your pharmacist.

REPORTING SUSPECTED SIDE EFFECTS

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

Report online at www.healthcanada.gc.ca/medeffect
Call toll-free at 1-866-234-2345

Complete a Canada Vigilance Reporting Form and:

- Fax toll-free to 1-866-678-6789, or
- Mail to: **Canada Vigilance Program
Health Canada
Postal Locator 0701D
Ottawa, Ontario
K1A 0K9**

Postage paid labels, Canada Vigilance Reporting Form and the adverse reaction reporting guidelines are available on the MedEffect™ Canada Web site at www.healthcanada.gc.ca/medeffect.

NOTE: Should you require information related to the management of side effects, contact your health professional. The Canada Vigilance Program does not provide medical advice.

MORE INFORMATION

This document plus the full Product Monograph, prepared for health professionals may be obtained by contacting the sponsor, Pfizer Canada Inc., at: 1-800-463-6001, or www.pfizer.ca

This leaflet was prepared by Pfizer Canada Inc.

Last revised: March 6, 2018